Yuyu Pharma (000220) Fundamentals 2026 — P/E 6.8x, Revenue Analysis | SniperIQ
Yuyu Pharma (000220) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩56.7B, trading at ₩3600.00 on the KSC. This SniperIQ fundamentals page covers Yuyu Pharma's valuation (P/E 6.8x, P/B 0.4x), profitability (net margin 6.3%), revenue (₩140.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Yuyu Pharma's market cap?
Yuyu Pharma (000220) has a market capitalization of approximately ₩56.7B, trading at ₩3600.00 on the KSC. Market cap moves with the live share price.
What is Yuyu Pharma's P/E ratio?
Yuyu Pharma's trailing twelve-month P/E ratio is 6.8x, with a price-to-book (P/B) of 0.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Yuyu Pharma?
Yuyu Pharma runs a net profit margin of 6.3%, a gross margin of 37.9%, and an operating margin of 7.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Yuyu Pharma generate?
Yuyu Pharma reported revenue of ₩140.9B for fiscal year 2025, with net income of ₩8.2B and earnings per share (EPS) of 492. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Yuyu Pharma pay a dividend?
Yuyu Pharma offers a trailing dividend yield of about 3.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Yuyu Pharma financially healthy?
Yuyu Pharma carries a debt-to-equity ratio of 0.20x and a current ratio of 1.68x, with a market beta of 0.35. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Yuyu Pharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Yuyu Pharma (000220) the key facts are: market cap ₩56.7B, P/E 6.8x, revenue ₩140.9B, 52-week range 3535-5100. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Yuyu Pharma's full fundamentals live
Get Yuyu Pharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.